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For over a decade the term “Big data” has been used to describe the rapid increase
in volume, variety and velocity of information available, not just in medical research but
in almost every aspect of our lives. As scientists, we now have the capacity to rapidly
generate, store and analyse data that, only a few years ago, would have taken many
years to compile. However, “Big data” no longer means what it once did. The term has
expanded and now refers not to just large data volume, but to our increasing ability
to analyse and interpret those data. Tautologies such as “data analytics” and “data
science” have emerged to describe approaches to the volume of available information
as it grows ever larger. New methods dedicated to improving data collection, storage,
cleaning, processing and interpretation continue to be developed, although not always
by, or for, medical researchers. Exploiting new tools to extract meaning from large volume
information has the potential to drive real change in clinical practice, from personalized
therapy and intelligent drug design to population screening and electronic health record
mining. As ever, where new technology promises “Big Advances,” significant challenges
remain. Here we discuss both the opportunities and challenges posed to biomedical
research by our increasing ability to tackle large datasets. Important challenges include
the need for standardization of data content, format, and clinical definitions, a heightened
need for collaborative networks with sharing of both data and expertise and, perhaps
most importantly, a need to reconsider how and when analytic methodology is taught to
medical researchers. We also set “Big data” analytics in context: recent advances may
appear to promise a revolution, sweeping away conventional approaches to medical
science. However, their real promise lies in their synergy with, not replacement of,
classical hypothesis-driven methods. The generation of novel, data-driven hypotheses
based on interpretable models will always require stringent validation and experimental
testing. Thus, hypothesis-generating research founded on large datasets adds to, rather
than replaces, traditional hypothesis driven science. Each can benefit from the other and
it is through using both that we can improve clinical practice.
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INTRODUCTION
Advances in technology have created—and continue to create—
an increasing ability to multiplex measurements on a single
sample. This may result in hundreds, thousands or even millions
of measurements being made concurrently, often combining
technologies to give simultaneous measures of DNA, RNA,
protein, function alongside clinical features including measures
of disease activity, progression and related metadata. However,
“Big data” is best considered not in terms of its size but of
its purpose (somewhat ironically given the now ubiquitous use
of the “Big” epithet; however we will retain the capital “B”
to honor it). The defining characteristic of such experimental
approaches is not the extended scale of measurement but the
hypothesis-free approach to the underlying experimental design.
Throughout this review we define “Big data” experiments as
hypothesis generating rather than hypothesis driven studies.
While they inevitably involve simultaneous measurement of
many variables—and hence are typically “Bigger” than their
counterparts driven by an a priori hypothesis—they do so in
an attempt to describe and probe the unknown workings of
complex systems: if we can measure it all, maybe we can
understand it all. By definition, this approach is less dependent
on prior knowledge and therefore has great potential to indicate
hitherto unsuspected pathways relevant to disease. As is often
the case with advances in technology, the rise of hypothesis-
free methods was initially greeted with a polarized mixture
of overblown enthusiasm and inappropriate nihilism: some
believed that a priori hypotheses were no longer necessary (1),
while others argued that new approaches were an irrelevant
distraction from established methods (2). With the vantage
point of history, it is clear that neither extreme was accurate.
Hypothesis-generating approaches are not only synergistic with
traditional methods, they are dependent upon them: after all,
once generated, a hypothesis must be tested (Figure 1). In this
way, Big data analyses can be used to ask novel questions, with
conventional experimental techniques remaining just as relevant
for testing them.
However, lost under a deluge of data, the goal of
understanding may often seem just as distant as when we
only had more limited numbers of measurements to contend
with. If our goal is to understand the complexity of disease, we
must be able to make sense of the complex volumes of data that
can now be rapidly generated. Indeed, there are few systemsmore
complex than those encountered in the field of biomedicine.
The idea that human biology is composed of a complex
network of interconnected systems is not new. The concept of
interconnected “biological levels” was introduced in the 1940s
(3) although a reductionist approach to biology can trace roots
back as far as Descartes, with the analogy of deconstructing a
clockwork mechanism prevalent from Newton (4) to Dawkins
(5). Such ideas have informed the development of “systems
biology,” in which we aim to arrive at mechanistic explanations
for higher biological functions in terms of the “parts” of the
biological machine (6).
The development of Big data approaches has greatly
enhanced our ability to probe which “parts” of biology may
be dysfunctional. The goal of precision medicine aims to take
FIGURE 1 | The synergistic cycle of hypothesis-driven and data-driven
experimentation.
this approach one step further, by making that information of
pragmatic value to the practicing clinician. Precision medicine
can be succinctly defined as an approach to provide the right
treatments to the right patients at the right time (7). However, for
most clinical problems, precision strategies remain aspirational.
The challenge of reducing biology to its component parts, then
identifying which can and should be measured to choose an
optimal intervention, the patient population that will benefit
and when they will benefit most cannot be overstated. Yet the
increasing use of hypothesis-free, Big data approaches promises
to help us reach this aspirational goal.
In this review we summarize a number of the key challenges in
using Big data analysis to facilitate precision medicine. Technical
and methodological approaches have been systemically discussed
elsewhere and we direct the reader to these excellent reviews
(8–10). Here we identify key conceptual and infrastructural
challenges and provide a perspective on how advances can be
and are being used to arrive at precision medicine strategies with
specific examples.
ACCESS AND TECHNICAL
CONSIDERATIONS FOR HARNESSING
MEDICAL BIG DATA
The concept of Big data in medicine is not difficult to grasp:
use large volumes of medical information to look for trends
or associations that are not otherwise evident in smaller data
sets. So why has Big data not been more widely leveraged?
What is the difference between industries such as Google, Netflix
and Amazon that have harnessed Big data to provide accurate
and personalized real time information from on line searching
and purchasing activities, and the health care system? Analysis
of these successful industries reveals they have free and open
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access to data, which are provided willingly by the customer
and delivered directly and centrally to the company. These
deep data indicate personal likes and dislikes, enabling accurate
predictions for future on-line interactions. Is it possible that
large volume medical information from individual patient data
could be used to identify novel risks or therapeutic options
that can then be applied at the individual level to improve
outcomes? Compared with industry, for the most part, the
situation is different in healthcare. Medical records, representing
deep private personal information, is carefully guarded and not
openly available; data are usually siloed in clinic or hospital
charts with no central sharing to allow the velocity or volume of
data required to exploit Big data methods. Medical data is also
complex and less “usable” compared with that being provided to
large companies and therefore requires processing to provide a
readily usable form. The technical infrastructure even to allow
movement, manipulation andmanagement of medical data is not
readily available.
Broadly speaking, major barriers exist in the access to data,
which are both philosophical and practical. To improve the
translation of existing data into new healthcare solutions, a
number of areas need to be addressed. These include, but are not
limited to, the collection and standardization of heterogeneous
datasets, the curation of the resultant clean data, prior informed
consent for use of de-identified data, and the ability to provide
these data back to the healthcare and research communities for
further use.
Industry vs. Medicine: Barriers and
Opportunities
By understanding the similarities and the differences between
clinical Big data and that used in other industries it is possible
to better appreciate some opportunities that exist in the clinical
field. It is also possible to understand why the uptake and
translation of these techniques has not been a simple transfer
from one domain to another. Industry uses data that can truly
be defined as Big (exhibiting large volume, high velocity, and
variety) but tends to be of low information density. These
data are usually free, arising from an individual’s incidental
digital footprint in exchange for services. These data provide
a surrogate marker of an activity that allows the prediction
of patterns, trends, and outcomes. Fundamentally, data is
acquired at the time services are accessed, with those data being
either present or absent. Such data does exist in the clinical
setting. Examples include physiological monitoring during an
operation from multiple monitors providing high volume, high
velocity and varied data that requires real time handling for
the detection of data falling outside of a threshold that alerts
the attending clinician. An example of lower volume data
is the day to day accumulation of clinical tests that add to
prior investigations providing updated diagnoses and medical
management. Similarly, the handling of population based clinical
data has the ability to predict trends in public health such
as the timing of infectious disease epidemics. For these data
the velocity provides “real time” prospective information and
allows trend prediction. The output is referable to the source
of the data, i.e., a patient in the operating room or a specific
geographical population experiencing the winter flu season
[Google Flu Trends (11)].
This real time information is primarily used to predict
future trends (predictive modeling) without trying to provide
any reasons for the findings. A more immediate target for Big
data is the wealth of clinical data already housed in hospitals
that help answer the question as to why particular events
are occurring. These data have the potential, if they could be
integrated and analyzed appropriately, to give insights into the
causes of disease, allow their detection and diagnosis, guide
therapy, and management, plus the development of future drugs
and interventions. To assimilate this data will require massive
computing far beyond an individual’s capability thus fulfilling
the definition of Big data. The data will largely be derived
from and specific to populations and then applied to individuals
(e.g., patient groups with different disease types or processes
provide new insights for the benefit of individuals), and will
be retrospectively collected rather than prospectively acquired.
Finally, while non-medical Big data has largely been incidental,
at no charge and with low information density, the Big data
of the clinical world will be acquired intentionally, costly (to
someone) with high information density. This is therefore more
akin to business intelligence which requires Big data techniques
to derive measurements, and to detect trends (not just predict
them), which are otherwise not visible or manageable by human
inspection alone.
The clinical domain has a number of similarities with
the business intelligence model of Big data which potentially
provides an approach to clinical data handling already tested in
the business world.
Within the electronic health record, as in business, data are
both structured and non-structured and technologies to deal with
both will be required to allow easy interpretation. In business, this
allows the identification of new opportunities and development
of new strategies which can be translated clinically as new
understanding of disease and development of new treatments.
Big data provides the ability to combine data from numerous
sources both internal and external to business; similarly,
multiple data sources (clinical, laboratory tests, imaging, genetics,
etc.) may be combined in the clinical domain and provide
“intelligence” not derived from any single data source, invisible
to routine observation. A central data warehouse provides a site
for integrating this varied data allowing curation, combination
and analysis. Currently such centralized repositories do not
commonly exist in clinical information technology infrastructure
within hospitals. These data repositories have been designed
and built in the pre-Big data era being standalone and siloed,
with no intention of allowing the data to be combined and
then analyzed in conjunction with various data sets. There
is a need for newly installed information technology systems
within clinical domains to ensure there is a means to share data
between systems.
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Philosophy of Data Ownership
Patient data of any sort, because it is held within medical
institutions, appears to belong to that institution. However,
these institutions merely act as the custodians of this data—the
data is the property of the patient and the access and use of
that data outside of the clinical realm requires patient consent.
This immediately puts a brake on the rapid exploitation of the
large volume of data already held in clinical records. While
retrospective hypothesis driven research can be undertaken on
specific, anonymized data as with any research, once the study
has ended the data should be destroyed. For Big data techniques
using thousands to millions of data points, which may have
required considerable processing, the prospect of losing such
valuable data at the end of the project is counter-intuitive for
the advancement of medical knowledge. Prospective consent
of the patient to store and use their data is therefore a more
powerful model and allows the accumulation of large data sets
then allowing the application of hypothesis driven research
questions to those data. While not using the vast wealth of
retrospective data feels wasteful, the rate (velocity) at which
new data are accrued in the medical setting is sufficiently rapid
that the resultant consented data is far more valuable. This
added step of acquiring consent from patients likely requires
on site manpower to interact with patients. Alternatively,
options such as patients providing blanket consent for use
of their data may be an option but will need fully informed
consent. This dilemma has been brought to the fore by the EU
General Data Protection Regulation (GDPR) which entered into
force in 2018, initiating an international debate on Big data
sharing in health (12).
Regulations Regarding Data Sharing
On April 27, 2016, the European Union approved a new set
of regulations around privacy: the General Data Protection
Regulation (GDPR) (13), which is in effect since May 25, 2018.
The GDPR applies if the data controller (the organization that
collects data), data processor (the organization that processes
data on behalf of the data controller) or data subject is based
in the EU. For science, this means that all studies performed
by European institutes/companies and/or on European citizens,
will be subject to the GDPR, with the exception of data
that is fully anonymized (14). The GDPR sets out seven
key principles: lawfulness, fairness and transparency; purpose
limitation; data minimization; accuracy; storage limitation;
integrity and confidentiality (security); and accountability. The
GDPR puts some constraints on data sharing, e.g., if a data
controller wants to share data with another data controller,
he/she needs to have an appropriate contract in place, particularly
if that other data controller is located outside the EU (15).
If a data controller wants to share data with a third party,
and that third party is a processor, then a Data Processor
Agreement (DPA) needs to be made. Apart from this DPA,
the informed consent that the patient signs before participating
in a study, needs to state clearly for what purposes their
data will be used (16). Penalties for non-compliance can be
significant, GDPR fines are up to e20 million or 4% of
annual turnover. Considering the fact that health data are
“sensitive,” potential discrimination has been addressed in
legislation and a more proportionate approach is applied to
balance privacy rights against the potential benefits of data
sharing in science (12). In fact, processing of “data concerning
health,” “genetic data,” and “biometric data” is prohibited unless
one of several conditions applies: data subject gives “explicit
consent,” processing is necessary for the purposes of provision
of services or management of health system (etc.), or processing
is necessary for reasons of public interest in the area of
public health.
The question of “explicit consent” of patients for their
healthcare data to be used for research purposes provoked intense
debate already during negotiations for GDPR, but finally these
research groups lost the argument in the European political
arena to advocacy groups of greater privacy. Research groups
lobbied that restricting access to billions of terabytes of data
would hold back research e.g., into cancer in Europe. The fear
as concluded by Professor Subhajit Basu, from Leeds University,
is that “GDPR will make healthcare innovation more laborious
in Europe as lots of people won’t give their consent. It will
also add another layer of staff to take consent, making it more
expensive. We already have stricter data protection laws than the
US and China, who are moving ahead in producing innovative
healthcare technology.” (17)
Within the GDPR, the data subject also has the “right to
be forgotten”: he/she can withdraw the consent, after which
the data controller needs to remove all his/her personal data
(18). Because of all issues around data sharing, scientists might
consider (whenever possible) to share only aggregated data which
cannot be traced back to individual data subjects, or to raise the
abstraction level, sharing insights instead of data (19).
While the implementation of GDPR has brought this
issue into sharp focus, it has not resolved a fundamental
dilemma. As clinicians and scientists, we face an increasingly
urgent need to balance the opportunity Big data provides
for improving healthcare, against the right of individuals to
control their own data. It is our responsibility to only use
data with appropriate consent, but it is also our responsibility
to maximize our ability to improve health. Balancing these
two will remain an increasing challenge for all precision
medicine strategies.
Sharing of Data, Experience and
Training—FAIR Principles
The sharing of data only makes sense when these data are
structured properly [preferably using an ontology such as BFO,
OBO, or RO (20)], contains detailed descriptions about what each
field means (metadata) and can be combined with other data
types in a reliable manner. These tasks are usually performed by
a data manager or data steward (21), a function that has been
gaining importance over the past years, due to the rise of “Big
data.” Until recently, data managers and data stewards had to
do their job without having a clear set of rules to guide them.
In 2016 however, the FAIR Guiding Principles for scientific data
management and stewardship (22) were published. FAIR stands
for the four foundational principles—Findability, Accessibility,
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TABLE 1 | FAIR principles for data management and stewardship.
1 Findability: (meta)data are assigned a globally unique and persistent identifier;
data are described with rich metadata; metadata clearly and explicitly include
the identifier of the data it describes; (meta)data are registered or indexed in a
searchable resource
2 Accessibility: (meta)data are retrievable by their identifier using a standardized
communications protocol; this protocol is open, free, and universally
implementable, and allows for an authentication and authorization procedure,
where necessary; metadata are accessible, even when the data are no longer
available
3 Interoperability: (meta)data use a formal, accessible, shared, and broadly
applicable language for knowledge representation; they use vocabularies that
follow FAIR principles; they include qualified references to other (meta)data
4 Reusability: (meta)data are richly described with a plurality of accurate and
relevant attributes; they are released with a clear and accessible data usage
license; they are associated with detailed provenance; they meet
domain-relevant community standards
Interoperability, and Reusability—that serve to guide data
producers and publishers as they navigate around the obstacles
around data management and stewardship. The publication
offers guidelines around these four principles (Table 1).
Physical Infrastructure
On first impression, healthcare institutions are well equipped
with information technology. However, this has been designed
to support the clinical environment and billing, but not the
research environment of Big data. Exploitation of this new
research environment will require a unique environment to
store, handle, combine, curate and analyse large volumes of
data. Clinical systems are built to isolate different data sets
such as imaging, pathology and laboratory tests, whereas the
Big data domain requires the integration of data. The EHR
may provide some of this cross referencing of unstructured
data but does not give the opportunity for deriving more
complex data from datasets such as imaging and pathology
which gives the opportunity for further analysis beyond
the written report. To do this, as mentioned above, a data
warehouse provides a “third space” for housing diverse data
that normally resides elsewhere. This allows the handling
of multiple individuals at the same time, grouped by
some common feature such as disease type or imaging
appearance, which is the opposite of a clinical system
which usually is interested in varied data from one patient
at a time.
A data warehouse allows secondary handling to generate
cleaner, more information-rich data as seen when applying
annotations and segmentation in pathological and radiological
images. In order to achieve this, the data warehouse needs
to provide the interface with multiple software applications.
Within the warehouse, the researcher can gather varied, high
volume data that can then undergo various pre-processing
techniques in readiness for the application of Big data techniques
including artificial intelligence and machine learning. The
latter needs specialized high-powered computing to achieve
rapid processing. Graphic processing units (GPUs) allow the
handling of very large batches of data, and undertake repetitive
operations that can accelerate processing by up to a hundred
times compared to standard central processing units (CPU’s).
As previously stated, current data handling systems are not
yet equipped with these processors requiring upgrading of
hardware infrastructure to translate these new techniques into
the clinical domain. The connection of these supercomputing
stacks to the data can potentially be achieved via the central
data warehouse containing the pre-processed data drawn from
many sources.
Clinical Translation
A significant barrier to the application of new Big data techniques
into clinical practice is the positioning of these techniques in
the current clinical work environment. New and disruptive
technologies provided by Big data analytics are likely to be just
that. . . disruptive. Current clinical practice will need to undergo
change to incorporate these new data driven techniques. There
may need to be sufficient periods of testing of new techniques,
especially those which in some way replace a human action
and speed the clinical process. Those that aid this process by
prioritizing worklists or flagging urgent findings are likely to
diffuse rapidly into day to day usage. Similarly, techniques not
previously possible because of the sheer size of data being handled
are likely to gain early adoption. A major player in achieving
this process will be industry which will enable the incorporation
of hardware and software to support Big data handling in the
current workflow. If access to data and its analysis is difficult and
requires interruption of the normal clinical process, uptake will
be slow or non-existent. A push button application on a computer
screen however, as on an x-ray image viewer that seamlessly
activates the program in the background is far more likely to
be adopted. Greater success will be achieved with the automatic
running of programs triggered by image content and specific
imaging examinations. As previously mentioned, these programs
could potentially provide identification of suspicious regions
in complex images requiring further scrutiny or undertake
quantitative measurements in the background which are then
presented through visualization techniques in conjunction with
the qualitative structured report. Furthermore, quantitative data
can then be compared with that from large populations to
define its position in the normal range and, from this and other
clinical data, provide predictive data regarding drug response,
progression and outcome. Part of the attraction for industry in
this rapidly expanding arena will obviously be the generation
of Intellectual Property (IP). Development of new techniques
useful to clinical departments will require close collaboration
between industry and clinical researchers to ensure developments
are relevant and rigorously tested in real life scenarios.
IP protection—provided mainly via patents—is the pillar of
national research policies and essential to effectively translate
innovation by commercialization. In the absence of such
protection, companies are unlikely to invest in the development
of diagnostic tests or treatments (23). However, the operation
of the IP system is being fundamentally changed by Big
data based technical solutions. Due to free and open source
software tools for patent analytics (24) and technical advances
in patent searches such as visualization techniques it is easy
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to gain access to high quality inventions and intellectual
property being developed and to understand the findings.
Today, unlike a traditional state-of-the-art search which provides
relevant information in text format, patent landscape analysis
provides graphics and charts that demonstrate patenting trends,
leading patent assignees, collaboration partners, white space
analysis, technology evaluations (25). By using network based
and Big data analysis, important patent information including
owner, inventor, attorney, patent examiner or technology can
be determined instantly. Presently, patent portfolios are being
unlocked and democratized due to free access to patent
analysis. In the near future, automated patent landscaping may
generate high-quality patent landscapes with minimal effort
with the help of heuristics based on patent metadata and
machine learning thereby increasing the access to conducting
patent landscape analysis (26). Although such changes within
the operation of the IP system gives new possibilities to
researchers, it is hard to forecast the long-term effect,
whether and how incentives in health research will be shifted
(encouraging/discouraging innovation).
The Bigger the Better? Challenges in
Translating From Big Data
Just as the volume of data that can be generated has increased
exponentially, so the complexity of those data have increased. It
is no longer enough to sequence all variants in a human genome,
now we can relate them to transcript levels, protein levels,
metabolites or functional and phenotypic traits also. Moreover,
it has become clear that reconstruction of single cell data may
provide significantly more insight into biological processes as
compared to bulk analysis of mixed populations of cells (27).
It is now possible to measure concurrent transcriptomes and
genetics [so-called G&T seq (28)] or epigenetic modifications
(29) on a single cell. So, as the volume of data increases, so does
its complexity. Integrating varied Big data from a set of samples,
or from a partially overlapping set of samples, has become a new
frontier of method development. It is not the goal of this review
to provide a comprehensive review of such methods [which
have been comprehensively and accessibly reviewed elsewhere
(8)] but instead to highlight core challenges for generating,
integrating, and analysing data such that it can prove useful
for precision medicine.
Forged in the Fire of Validation: The
Requirement for Replication
While new technologies have greatly increased our ability to
generate data, old problems persist and are arguably accentuated
by hypothesis-generating methods. A fundamental scientific
tenet holds that, for a result to be robust, it must be reproducible.
However, it has been reported that results from a concerning
proportion of even the highest ranking scientific articles may
not be reproduced [∼11% only were (30)]. Granted this was
a restricted set of highly novel preclinical findings and the
experimental methods being used were in some cases advanced
enough to require a not always accessible mastery/sophistication
for proper execution. Still, the likelihood that such independent
validation will even be attempted, let alone achieved, inevitably
falls as the time, energy and cost of generating data increases.
Big data is often expensive data but we should not allow a shift
toward hypothesis-free experimentation to erode confidence in
the conclusions being made. The best—arguably the only—way
to improve confidence in the findings from Big data is to work to
facilitate transparent validation of findings.
Where the number of measures (p) greatly outstrips the
number of samples they are made on (n), the risk of “overfitting”
becomes of paramount importance. Such “p>> n” problems are
common in hypothesis-generating research. When an analytical
model is developed, or “fitted,” on a set of Big data (the “training”
set), the risk is that the model will perform extremely well
on that particular dataset, finding the exact features required
to do so from the extensive range available. However, for that
model to perform even acceptably on a new dataset (the “test”
set), it cannot fit the training set too well (i.e., be “over-fitted,”
Figure 2). A model must be found that both reflects the data and
is likely to generalize to new samples, without compromising too
much the performance on the training set. This problem, called
model “regularization,” is common to many machine-learning
FIGURE 2 | The concept of overfitting and model regularization.
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approaches (31) and is of increasing importance as data volume
and complexity increases.
For example, if a large dataset (perhaps 100 k gene expression
measures on 100 patients/controls by RNA sequencing) is
analyzed, a clear model may be found using 20 genes whose
expression allows clean separation of those with/without disease.
This may appear to be a useful advance, allowing clean
diagnosis if the relevant genes are measured. While the result
is encouraging, it is impossible to tell at this stage whether the
discriminating model will prove useful or not: its performance
can only be assessed on samples that were not used to generate
the model in the first place. Otherwise, it looks (and is) too good
to be true. Thus, replication in a new, independent data set is
absolutely required in order to obtain a robust estimate of that
models performance (Figure 3).
While this example is overly simplistic, overfitting remains
an insidious obstacle to the translation of robust, reproducible
hypotheses from biomedical Big data. Overfitting occurs easily
and is all the more dangerous because it tells us what we
want to hear, suggesting we have an interesting result, a strong
association. Risk of overfitting is also likely to increase as the
complexity of data available increases, i.e., as p increases. To
counter that, increasing the number of independent samples
(n) becomes fundamental. As surprising at it may seem, in the
early days of RNA-seq, experiments were performed with no
replicates, leading to prominent genomic statisticians to remind
the community that next-generation sequencing platforms are
simply high-throughput measurement platforms still requiring
biological replication (32). As we accumulate genomics data of
several kinds across a spectrum of diseases, estimating effect sizes
becomes more accurate and more accessible. In turn, realistic
effect sizes enable a priori power calculations and/or simulations,
which help reveal whether a study is sufficiently sensitive, or
rather doomed by either false negatives or spurious correlations.
Yet generating sufficient samples and funds to process
independent cohorts can be challenging at the level of an
individual academic lab. That is why performing science at
the scale of networks of labs or even larger international
consortia is essential to generate reliable, robust and truly big
(as in big n, not big p) biomedical/genomic datasets. Funding
agencies have widely embraced this concept with collaborative
funding models such as the U and P grant series, and large-
scale initiatives such as ENCODE, TCGA, BRAIN from the
NIH or Blueprint in the EU, to mention just a few. Training
FIGURE 3 | Model performance evaluation.
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datasets need to be large enough to allow discovery, with
comparable test datasets available for independent validation.
Leave-one-out cross-validation approaches (LOOCV, where one
sample is re-iteratively withheld from the training set during
model development to allow an independent estimate of
performance) are useful and can be built into regularization
strategies (31) (Figure 3). However, changes in the way the
biomedical community works, with increasing collaboration and
communication is also facilitating validation of models built on
Big data.
Community Service: The Bigger the Better?
The development of international consortia and networks
facilitating sample collection and distribution facilitate access
to precious biomaterials from patients. Such biorepositories can
provide access to carefully annotated samples, often including
a wide range of assay materials and with detailed metadata.
This can rapidly expand the pool of samples available for
the generation of large datasets. Examples include the TEDDY
and TrialNet consortia in diabetes (33, 34), the UK Biobank
(35) and the Immune Tolerance Network (ITN), in which
samples from completed clinical trials can be accessed by
collaborators in conjunction with detailed clinical metadata
through the TrialShare platform (36). This allows clinical
trials to create value far beyond answering a focused primary
or restricted secondary endpoints. This model is further
extended in attempts to build similar biorepositories from
pharmaceutical industry trials in which the placebo arms can
be compiled into a single meta-study for new discovery work
(37). A positive side-effect of large international consortia
is that the complexity of coordination requires developing
well-defined standard operating procedures (SOPs) for both
experimental and analytical procedures. Because consortia
group together so many experts in a particular field, the
resulting (public) SOPs often become the standard de facto
resource for the task at hand. For example, ChIP-seq protocols
from the ENCODE initiative (http://www.encodeproject.org/
data-standards), as well as its bioinformatics pipelines (http://
www.encodeproject.org/pipelines), are often referred to by a
constellation of published studies having no formal connection
with the primary initiative.
It is not just biosamples that are increasingly being shared, but
also data. In addition to the example networks above, the Cancer
Genome Atlas has generated—and made publicly available—
integrated molecular data on over 10,000 samples from 33
different tumor types. This huge, collaborative project not
only references genetic, epigenetic, transcriptomic, histologic,
proteomic, and detailed clinical data but does so in the context
of an accessible data portal facilitating access and use (38).
Most importantly, there is clear evidence that this approach
can work, with cancer-associated mutation identification driving
target identification and precision medicine trials (39).
Forming a community of researchers can do more than
simply collect samples to be used in data generation. Harnessing
the analytical experience of a community of researchers is the
explicit goal of crowdsourcing approaches such as that used
by the DREAM challenges [Dialogue for Research Engineering
Assessments and Methods (40)]. This alternative model of
data sharing and analysis effectively reverses the conventional
flow of data between repositories and analysts. Community
sourced, registered users can access data and effectively compete
against each other to train optimal models. Importantly, the
ultimate “winner” is determined by validation on independent
“containerized” datasets, controlling the risk of overfitting
during development. This innovative approach has facilitated
not only broader access to key datasets but has also engaged
the analytic community broadly with notable successes (41).
Indeed, following centralized cloud-based processing of several
challenges, consistent themes have emerged from successful
models. Core principles of successful models have been their
simplicity and inclusion of approaches either integrating different
models or prior knowledge of the relevant field (8). In
particular, this last observation has important ramifications for
the integration of biomedical and analytical training (see below).
Arguably the most remarkable success in the field of Big
data receives almost no attention. Despite significant potential
for the creation of protectable value, software developers have
almost universally made source code freely available through
open-source tools that are frequently adapted and improved by
the scientific community (42). Encouraged by organizations such
as the Open Bioinformatics Foundation and the International
Society for Computational Biology, this quiet revolution has
undoubtedly had a huge impact on the rate of progress and
our ability to harness the potential of Big data and continues
to do so.
Setting Standards
In order for robust validation to work, it is necessary to ensure
that measurements made in a training cohort are comparable to
those made in a test set. This sounds straightforward, but isn’t.
Robust analysis can fail to validate just as easily as overfitted
analysis, particularly where patients may come from different
healthcare systems, samples may be collected in different ways
and data may be generated using different protocols.
While there has been remarkable progress in detection
of disease using a single blood sample (such as genome
sequencing in affected individuals, circulating cell free tumor
DNA in oncology, non-invasive prenatal testing in pregnancy,
among others), it is no longer enough to provide all the
information about an individual with respect to one’s health.
There is an increased understanding of the need for repeat
sampling to gather longitudinal data, to measure changes over
time with or without a significant exposure (43, 44). More
importantly, the ability to interrogate single cells has spurred
a need to identify and isolate the tissue of interest and select
appropriate samples from within that tissue (45). Tissue samples
include blood, saliva, buccal swabs, organ-specific such as in
tumors, as well as stool samples for the newly emerging field
of microbiome.
Over the past two decades, methods have been established
to ensure standardization of extracted genomic material such as
DNA from blood and other fresh tissues, including automation
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(46). However, other samples such as DNA from paraffin
embedded tissue, RNA, protein are more sensitive to type of
tissue and tissue handling, and may not be robust enough for
replication studies. For Big data science to work, one of the key
ingredients is robust and reproducible input data. In this regard,
there have been recent advancements in attempts to standardize
the way these samples are collected for generating “omics” data
(47–49). Basic experimental methodologies involved in sample
collection or generation are crucial for the quality of genomics
datasets, yet, in practice, they are often neglected. Twenty-
First century omics-generating platforms are often perceived
to be so advanced and complex, particularly to the novice,
that should draw most of the planning effort, leaving details
on trivial Twentieth-century steps (cell culture, cell freezing,
nucleic acid isolation) comparatively overlooked. If anything,
while experiments performed on poorly generated material
would yield only a handful of flawed data points in the
pre-genomics era, they would bias thousands of data points
at once in the big data era. When thinking at the reasons
underlying failed or low-quality omics experiments in daily
practice, it is easy to realize that trivialities and logistics played
a major role, while sequencing and proteomics platforms are
seldom the culprit.
Similar considerations apply when choosing the starting
biologic material for a big data experiments. Because of
its accessibility, blood is still the most widely available
tissue in human research and is often well suited for
investigating immune-related diseases. However, peripheral
blood mononuclear cells (PBMCs) are a complex mixture of
immune cell types. Immune profiling using omics technologies
is overwhelmingly performed on total PBMCs, as opposed
to more uniform cell subsets. While cutting-edge single-cell
platforms can deal with complex mixtures of cell types, the more
widespread bulk platforms, such as Illumina’s sequencers, can
only measure averages from a cell population. Unfortunately,
such averages are a function of both differential regulation
of mechanisms of interest (such as gene expression) and
the often-uninteresting differential prevalence of each cell
type—this latter effectively qualifying as unwanted noise, from
an experimentalist’s standpoint. This issue is often either
unappreciated or disregarded as solvable by deconvolution
algorithms, that is software that attempts to recover the
unmeasured signal from contributing subsets to the measured
mean. However, deconvolution software often deals with just
the main white blood cell subsets, leading to coarse resolution;
is usually trained on healthy controls, limiting its usefulness
in diseases substantially altering molecular fingerprints, such
as cancer; and its accuracy is severely limited (an extreme
example being CD4+ and CD8+ T cells, lymphocytes with a
clear immunological distinction, but sharing so much of the
epigenetics and transcriptional landscape to be very hard to
deconvolve separately) (50, 51).
Lastly, standardization of samples also allows for data
generated from one individual/ cohort to be used in other related
studies and obviates the need to generate the same data over and
over again. While this has to be within the remit of ethics and
data sharing regulations for each institution/ country, it allows
for better use of limited resources (such as clinical material)
and funds.
Data Comparability
The past decade has seen remarkable progress in development of
standard genomic data formats including FASTQ, BAM/CRAM,
and VCF files (52). However, such standardization is incomplete
and may lead to incompatibility between inputs and outputs of
different bioinformatics tools, or, worse, inaccurate results. An
example is the quality encoding format of FASTQ files, which
is not captured by the file itself, and must be either inferred or
transmitted as accompanying metadata with the file itself. Still,
even an imperfect standardization has allowed for sharing of
genomic data across institutions into either aggregated databases
such as ExAC, GNOMAD (53) or as federated database such as
Beacon Network (54). These databases allow for understanding
of genetic variations that are common across different ethnic
groups but also identifies variants that are unique within a
specific ethnic group (53). However, despite these successes with
upstream genomic data formats, key challenges remain regarding
further downstream data formats. This often leads to non-
uniform analysis, and indeed, re-analysis of the same data using
different pipelines yields different results (55, 56).
Similar efforts have been developed in the field of proteomics
(57) andmicrobiomics (49). In view of the increasing recognition
of a need for such standards. The American College of Medical
Genetics released guidelines to aid interpretation of genomic
variants (58), the ClinGen workgroup has released a framework
to establish gene-disease relationship (59) and Global Alliance for
Genomics and Health (GA4GH), in collaboration with National
Institute of Health (NIH), have developed genomic data toolkit
which includes standards for storage and retrieval of genomic
data (54).
Clinical and Phenotypic Definitions
One of the largest challenges with harmonizing Big data
is definition of cases (disease) and controls (health) (60).
Stating the obvious, no one is healthy for ever. Using strict
definitions based on consensus statements allow comparability
of diseases across different populations. There have been several
initiatives to standardize phenotypic terminology including
Human Phenotype Ontology (HPO), Monarch Initiative, among
others (61, 62). In addition, standard diagnostic codes such as
SNOMED CT, ICD-10, etc. provide for computer processable
codes which standardize medical terms and diagnosis, and lead
to consistent information exchange across different systems (63).
As we move toward use of machine learning and artificial
intelligence, the use of controlled vocabularies is critical. Even
more important is the need for robust definitions of the clinical
phenotypes and diagnosis that accompany these samples so
as to ensure accurate comparison between cases and controls.
The often heard phrase “Garbage in, Garbage out” is ever
more relevant in the days of Big data science (64). Establishing
clear principles on data access and sharing is a key step in
establishing and maintaining community-wide access to the
kind of collaborative sample sharing required to facilitate both
discovery and validation.
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Opportunities for Clinical Big Data:
Leveraging the Electronic Health Record
The EHR is an intrinsically large resource as the majority of
patients in the developed world are treated in this context. There
is a staggering amount of information collected longitudinally
on each individual, including laboratory test results, diagnoses,
free text, and imaging. This existing wealth of information
is available at virtually zero cost, collected systematically for
decades. Whereas the EHR has classically been used in clinical
care, billing, and auditing, it is increasingly used to generate
evidence on a large scale (65). Population-based studies tend
to be disease-specific, but the EHR is largely disease agnostic.
Thus the EHR provides opportunities to study virtually any
disease as well as pleiotropic influences of risk factors such as
genetic variation. Since the EHR was not originally designed
for evidence generation, leveraging these data is fraught with
challenges related to the collection, standardization, and curation
of data. While opportunities exist to study a spectrum of
phenotypes, data contained in the EHR is generally not as
rigorous or complete as that collected in a cohort-based
study. Nevertheless, these EHRs provide potential solutions
to problems involving Big data, including the reliability and
standardization of data and the accuracy of EHR phenotyping.
As discussed below, there are multiple examples of how these
challenges are being met by researchers and clinicians across
the globe.
Among the formidable challenges related to leveraging the
resources of the EHR is assurance of data quality. Missing data
abounds in these records and the study of many conditions
relies on mining narrative text with natural language processing
rather than more objective testing such as laboratory measures
and genomic sequencing. Misclassification is often encountered
within the electronic health record such as with International
Classification of Diseases-10th Revision (ICD-10) codes. EHR
data would also be improved by recording of lifestyle choices such
as diet and exercise, family history and relationships between
individuals, race and ethnicity, adherence to prescribed drugs,
allergies, and data from wearable technologies. Standardization
of data is also an issue. The EHR includes structured data
such as Systematized Nomenclature of Medicine-Clinical Terms
(SNOMED CT) terms and ICD-10 codes as well as unstructured
data such as medical history, discharge summaries, and imaging
reports in unformatted free text (65). Standardization across
multiple countries and EHR software tools provides a vast
opportunity for scalability. As the technical issues with EHR data
are addressed, legal and ethical frameworks will be necessary to
build and maintain public trust and ensure equitable data access.
Despite the many challenges that have yet to be addressed,
the EHR provides a wide variety of opportunities for improving
human health. The wealth of existing data that the EHR provides
enables richer profiles for health and disease that can be studied
on a population level. There is much effort in standardization
of EHR phenotyping, which has the potential to create sub-
categories of disease and eventually re-taxonomise diseases.
(66, 67) The EHR affords an opportunity for efficient and cost
effective implementation, allowing efficient return of data to
patient and provider. The integration of pharmacogenomics
testing into patient care is an example of the translational power
of the EHR (68, 69).
EHR data is increasingly being coupled to biorepositories,
creating opportunities to leverage “-omic” data in combination
with EHR phenotyping. Noteworthy examples include the UK
biobank and eMERGE Network (35, 70). With these new
resources, new and innovative tools are being developed, such as
the phenome-wide association study (PheWAS) (71, 72). Using
the PheWAS approach, genomic variation form biorepository
is systematically tested for association across phenotypes in
the EHR. The PheWAS approach presents a useful approach
to assess pleiotropy of genomic variants, allows the study of
human knockouts, and is a new approach to drug discovery
and drug repurposing. The coupling of EHR and -omic data
also enables translation of discovery back to the clinic. Such
biorepositories can mine genomic variation to confirm disease
diagnoses or re-diagnose/re-classify patients in a clinical setting.
In a recent study, combinations of rare genetic variants were
used to identify subsets of patients with distinct genetic causes
for common diseases that suffered severe outcomes such as
organ transplants (73). While illustrating the power of these
biorepositories, it is worth noting that these results were not
returnable to patients due to restrictions around the ethical
approval of the biorepository.
Artificial Intelligence and Clinical Imaging
While health improvements brought about by the application of
Big data techniques are still, largely, yet to translate into clinical
practice, the possible benefits of doing so can be seen in those
clinical areas already with large, easily available and usable data
sets. One such area is in clinical imaging where data is invariably
digitized and housed in dedicated picture archiving systems. In
addition, this imaging data is connected with clinical data in
the form of image reports, the electronic health record and also
carries its own metadata. Because of the ease of handling of this
data, it has been possible to show, at least experimentally, that
artificial intelligence through machine learning techniques, can
exploit Big data to provide clinical benefit. The need for these
high-powered computing techniques in part reflects the need
to extract hidden information from images which is not readily
available from the original datasets. This is in contrast to simple
parametric data within the clinical record including physiological
readings such as pulse rate or blood pressure, or results from
blood tests. The need for similar data processing is also seen in
digitized pathology image specimens.
Big data can provide annotated data sets to be used to train
artificial intelligence algorithms to recognize clinically relevant
conditions or features. In order for the algorithm to learn the
relevant features, which are not pre-programmed, significant
numbers of cases with the feature or condition under scrutiny
are required. Subsequently, similar, but different large volumes
of cases are used to test the algorithm against gold standard
annotations. Once trained to an acceptable level these techniques
have the opportunity to provide pre-screening of images to look
for cases with high likelihood of disease allowing prioritization
of formal reading. Screening tests such as breast mammography
could undergo pre-reading by artificial intelligence/machine
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learning to identify the few positive cases among the many
normal studies allowing rapid identification and turnaround.
Pre-screening of complex high acuity cases as seen in the trauma
setting also allow a focused approach to identify and review areas
of concern as a priority. Quantification of structures within an
image such as tumor volume, monitoring growth or response
to therapy, or cardiac ejection volume, to manage drug therapy
of heart failure or following heart attack, can be incorporated
into artificial intelligence/machine learning algorithms so they
are undertaken automatically rather than requiring painstaking
manual segmentation of structures.
As artificial intelligence/machine learning continues to
improve it has the ability to recognize image features without
any pre-training through the application of neural networks
which can assimilate different sets of clinical data. The
resultant algorithms can then be applied to similar, new clinical
information to predict individual patient responses based on
large prior patient cohorts. Alternatively, similar techniques
can be applied to images to identify sub populations that
are otherwise too complex to recognize. Furthermore, artificial
intelligence/machine learning may find a role in hypothesis
generation by identifying unrecognized, unique image features
or combination of features that relate to disease progression
or outcome. For instance, a subset of patients with memory
loss that potentially progress to dementia may have features
detectable prior to symptom development. This approach allows
large volume population interrogation with prospective clinical
follow up and identification of the most clinically relevant image
fingerprints, rather than analysis of small volume retrospective
data in patients who have already developed symptomatic
degenerative brain disease.
Despite the vast wealth of data contained in the clinical
information technology systems within hospitals, extraction of
usable data from the clinical domain is not a trivial task. This
is for a number of diverse reasons including: philosophy of data
handling; physical data handling infrastructure; the data format;
and translation of new advances into the clinical domain. These
problems must be addressed prior to successful application of
these new methodologies.
New Data, New Methods, New Training
It is clear that sample and phenotypic standardization provide
clear opportunities to add value and robust validation
through collaboration. However, increasing availability of
data has been matched by a shortage of those with the
skills to analyse and interpret those data. Data volume has
increased faster than predicted and, although the current
shortage of bioinformaticians was foreseen (74), corrective
measures are still required to encourage skilled analysts to
work on biomedical problems. Including prior knowledge of
relevant domains demonstrably improves the performance
of models built on Big data (8, 31), suggesting that, ideally,
analysts should not only be trained in informatics but in
biomedicine also.
Studies in the field of translational research usually collect
an abundance of data types: clinical data (demographics,
death/survival data, questionnaires, etc.), imaging data (MR,
UltraSound, PET, CT, and derived values), biosample data
(values from blood, urine, etc.), molecular data (genomics,
proteomics, etc.), digital pathology data, data from wearables
(blood pressure, heart rate, insulin level, etc.) and much more.
To combine and integrate these data types, the scientist needs
to understand both informatics (data science, data management,
and data curation) and the specific disease area. As there
are very many disease areas which all require their own
expertise, we will focus here on the informatics side: data
integration in translational research. Although this field is
relatively new, there are a number of online and offline
trainings available. As for the online trainings, Coursera offers
a course on “Big Data Integration and Processing” (75). The
i2b2 tranSMART Foundation, which is developing an open-
source/open-data community around the i2b2, tranSMART and
OpenBEL translational research platforms, has an extensive
training program available as well (76). As for the offline
trainings, ELIXIR offers a number of trainings around data
management (77). The European Bioinformatics Institute (EBI)
has created a 4-day course specific for multiomics data
integration (78).
REWARD AND ASSESSMENT OF
TRANSLATIONAL WORK
In order for the long, collaborative process of discovery toward
precision medicine to succeed, it is essential that all involved
receive proper recognition and reward. Increasing collaboration
means increasing length of authorship which, in turn, highlights
the increasing challenges inherent in conventional rewards for
intellectual contribution to a publication: in plain terms, if
there are over 5,000 authors (79), do only first and last really
count? The problem is particularly acute for those working
in bioinformatics (80). Encouraging early-career analysts to
pursue a biomedical career is challenging if the best they can
hope to receive is a mid-author position in a large study. The
backdrop to this problem is that similar analyst shortages in
other industries have resulted in more alternative options, often
better compensated than those in biomedicine (80). Reversing
this trend will require substantial changes to biomedical training,
with greater emphasis on analysis along with a revised approach
to incentives from academic institutions. Trainings such as
these in the analysis of big data would enable physicians and
TABLE 2 | Key proposed principles when assessing scientists.
1. Addressing societal needs is an important goal of scholarship.
2. Assessing faculty should be based on responsible indicators that reflect fully
the contribution to the scientific enterprise.
3. Publishing all research completely and transparently, regardless of the results,
should be rewarded.
4. The culture of Open Research needs to be rewarded
5. It is important to fund research that can provide an evidence base to inform
optimal ways to assess science and faculty.
6 Funding out-of-the-box ideas needs to be valued in promotion and tenure
decisions.
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researchers to not only enter the Big Data Cycle (Figure 1) on
the hypothesis-driven side, but also on the hypothesis-generating
side. There is an increasing recognition that traditional methods
of assessment and reward are outdated, with an international
expert panel convening in 2017 to define six guiding principles
toward identifying appropriate incentives and rewards for life
and clinical researchers [Table 2 (81)]. While these principles
represent a laudable goal, it remains to be seen if and how they
might be realized. At some institutions, computational biologists
are now promoted for contributing to team scientist as middle
authors while producing original work around developing novel
approaches to data analysis. Therefore, we would propose adding
a seventh principle here: “Developing novel approaches to
data analysis.”
SUMMARY AND CONCLUSIONS
In recent years the field of biomedical research has seen an
explosion in the volume, velocity and variety of information
available, something that has collectively become known as “Big
data.” This hypothesis-generating approach to science is arguably
best considered, not as a simple expansion of what has always
been done, but rather a complementary means of identifying and
inferring meaning from patterns in data. An increasing range of
“machine learning” methods allow these patterns or trends to be
directly learned from the data itself, rather than pre-specified by
researchers relying on prior knowledge. Together, these advances
are cause for great optimism. By definition, they are less reliant
on prior knowledge and hence can facilitate advances in our
understanding of biological mechanism through a reductionist
“systems medicine” approach. They can also identify patterns
in biomedical data that can inform development of clinical
biomarkers or indicate unsuspected treatment targets, expediting
a goal of precision medicine.
However, in order to fully realize the potential inherent
in the Big data we can now generate, we must alter
the way we work. Forming collaborative networks—sharing
samples, data, and methods—is now more important than ever
and increasingly requires building bridges to less traditional
collaborating specialities such as engineering, computer science
and to industry. Such increased interaction is unavoidable if
we are to ensure that mechanistic inferences drawn from Big
data are robust and reproducible. Infrastructure capacity will
require constant updating, while regulation and stewardship
must reassure the patients from whom it is sourced that their
information is handled responsibly. Importantly, this must be
achieved without introducing stringency measures that threaten
the access that is necessary for progress to flourish. Finally, it is
clear that the rapid growth in information is going to continue:
Big data is going to keep getting Bigger and the way we teach
biomedical science must adapt too. Encouragingly, there is clear
evidence that each of these challenges can be and is being met in
at least some areas. Making the most of Big data will be no mean
feat, but the potential benefits are Bigger still.
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